Clinical trials: Macular Edema, Diabetic
Diabetic Macular Edema
Combination OZURDEX® & EyLea® vs. OZURDEX® Monotherapy in IncompLete-Responders wIth Diabetic Macular Edema
COLLIDE is a multi-center, open-label, 1:1 randomized study looking at the effects of aflibercept (AFL; 2.0mg) plus OZURDEX (DEX; 0.7mg) implant combination therapy versus DEX monotherapy in phakic or pseudophakic eyes with…
- Trial name
- COLLIDE (NCT03629210)
- Testing
- OZURDEX, Eylea
- Sponsor
- Pradeepa Yoganathan
Diabetic Macular Edema
Outcomes After Vitrectomy in Eyes With Tractional Diabetic Macular Edema
1. assessment the outcomes of vitrectomy on retinal function by mf-ERG (multifocal electroretinogram) and anatomy by OCT (optical coherence tomography) in patients with tractional diabetic macular edema (TDME) . 2.
- Trial name
- NCT06316388
- Testing
- vitrectomy
- Volunteers
- 21 people
- Sponsor
- Rehab Azzam
Diabetic Macular Edema, Diabetic Retinopathy
ADVM-022 Intravitreal Gene Therapy for DME
A Phase 2, Multi-Center, Randomized, Double-Masked*, Active Controlled Study of ADVM-022 (AAV.7m8-aflibercept) in Subjects with Diabetic Macular Edema [INFINITY]
- Trial name
- INFINITY (NCT04418427)
- Testing
- 6E11 vg/eye of ADVM-022, 2E11 vg/eye of ADVM-022, Aflibercept
- Where
- 14 sites in United States, Puerto Rico
- Volunteers
- 36 people
- Sponsor
- Adverum Biotechnologies, Inc.
Diabetic Macular Edema (DME)
Multicenter Study to Evaluate the Efficacy of Treat and Extend Regimen of Aflibercept (EYLEA) as a Second Line Treatment for Diabetic Macular Edema
A 12-month, Multicenter Study to Evaluate the Efficacy of Treat and Extend Regimen (TER) of Aflibercept (EYLEA) 2mg /0.05 ml as a Second Line Treatment for Diabetic Macular Edema - TADI Study
- Trial name
- NCT02633852
- Testing
- Aflibercept
- Volunteers
- 48 people
- Sponsor
- Hadassah Medical Organization
Neovascular Age-related Macular Degeneration (NVAMD), Diabetic Macular Edema (DME)
A 2-part Study Consisting of Multiple Ascending Dose (MAD) Safety Study, and a Dose-finding Masked Study to Assess the Safety and Efficacy of Intravitreal (IVT) EYE103 in Patients With Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (NVAMD)
EYE103-101 is a 2-part study assessing safety and preliminary efficacy of EYE103 in patients with diabetic macular edema (DME) given as monotherapy or neovascular macular degeneration (NVAMD) given in combination with anti-VEGF.
- Trial name
- AMARONE (NCT05919693)
- Testing
- EYE103
- Where
- 32 sites in United States, Argentina and 2 more
- Volunteers
- 33 people
- Sponsor
- EyeBiotech Ltd.
Diabetic Retinopathy, Macular Edema
Treatment of Diabetic Macular Edema With Aflibercept in Subjects Previously Treated With Ranibizumab or Bevacizumab
Treatment of diabetic macular edema with intravitreal aflibercept in subjects previously treated with intravitreal anti-Vascular endothelial growth factor (VEGF) agents (ranibizumab or bevacizumab)
- Trial name
- SwapTwo (NCT02559180)
- Testing
- aflibercept
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Rishi Singh
Diabetic Macular Edema
Treatment for CI-DME in Eyes With Very Good VA Study
Although multiple studies have clearly demonstrated that ranibizumab therapy is more effective than laser alone for vision gain and avoiding vision loss in patients with central-involved Diabetic Macular Edema (DME), only eyes…
- Trial name
- Protocol V (NCT01909791)
- Testing
- Prompt Laser, Prompt aflibercept, Deferred laser
- Where
- 103 sites in United States, Canada
- Volunteers
- 702 people
- Sponsor
- Jaeb Center for Health Research
Diabetic Macular Edema
Effect of Intravitreal Bevacizumab on Clinically Significant Macular Edema
to compare the effect of intravitreal bevacizumab alone or in combination with triamcinolone acetonide with laser photocoagulation on clinically significant macular edema (CSME)
- Trial name
- NCT00370669
- Testing
- bevacizumab, triamcinolone acetonide
- Where
- Iran
- Volunteers
- 150 people
- Sponsor
- Shahid Beheshti University of Medical Sciences
Diabetic Macular Edema, Neovascular Age-related Macular Degeneration
Safety and Tolerability Study of UBX1325 in Patients With Diabetic Macular Edema or Neovascular Age-Related Macular Degeneration
A study to evaluate safety, tolerability, and pharmacokinetics of a single intravitreal injection of UBX1325 in patients diagnosed with diabetic macular edema (DME) or neovascular Age-Related Macular Degeneration.
- Trial name
- NCT04537884
- Testing
- UBX1325
- Where
- 8 sites in United States
- Volunteers
- 19 people
- Sponsor
- Unity Biotechnology, Inc.
Diabetic Macular Edema
Safety and Efficacy of Ranibizumab for Diabetic Macular Edema
The primary objective of the study is to assess the ocular and systemic adverse events of ranibizumab (Lucentis)for DME (diabetic macular edema) following previous treatment with intravitreal bevacizumab (Avastin).
- Trial name
- REACT (NCT01982435)
- Testing
- Ranibizumab
- Where
- 2 sites in United States
- Volunteers
- 27 people
- Sponsor
- Justis Ehlers
Diabetic Macular Edema
Sequentially Combined Vitrectomy, IVTA and Macular Focal Laser Photocoagulation for Diabetic Macular Edema
Macular edema constitutes the primary cause of visual impairment in diabetic patients with a disease duration of 20 years or more.
- Trial name
- NCT00371410
- Testing
- vitrectomy, intravitreal triamcinolone acetonide, macular focal laser photocoagulation
- Where
- South Korea
- Sponsor
- Samsung Medical Center
Diabetic Macular Edema
Efficacy and Safety of Conbercept for Diabetic Macular Edema Combined With Severe Non-proliferative Diabetic Retinopathy
The goal of this prospective multicenter open label study is to evaluate the efficacy and safety of intravitreal injection Conbercept (IVC) for the treatment of diabetic macular edema (DME) combined with severe nonproliferative…
- Trial name
- NCT06305143
- Testing
- Conbercept
- Where
- China
- Volunteers
- 58 people
- Sponsor
- Shanghai Eye Disease Prevention and Treatment Center
Macular Degeneration, Diabetic Retinopathy
A Phase 1 Safety Study of TG100801 Eye Drops in Healthy Volunteers
The formation of new blood vessels (angiogenesis), blood vessel leakage, and inflammation contribute to the progression of the eye disease, age-related macular degeneration (AMD), which is the leading cause of irreversible…
- Trial name
- NCT00414999
- Testing
- TG100801
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- TargeGen
Neovascular Age-related Macular Degeneration, Macular Oedema Secondary to RVO
A Trial to Evaluate the Safety and Usability of the SB15 PFS in Trial Participants With AMD, Macular Oedema Secondary to RVO, or Diabetic Macular Oedema
This is an open label, multicenter, Phase II trial to evaluate the safety and usability of the pre-filled syringe (PFS) of SB15 (Aflibercept biosimilar).
- Conditions
- Neovascular Age-related Macular Degeneration, Macular Oedema Secondary to RVO, Diabetic Macular Oedema
- Trial name
- NCT07844343
- Testing
- SB15 PFS
- Where
- 3 sites in South Korea
- Volunteers
- 33 people
- Sponsor
- Samsung Bioepis Co., Ltd.
Diabetic Macular Edema, Ischemic Maculopathy
Evaluation of the Effect of Intravitreal Injections of Anti-VEGF on Macular Perfusion in Diabetic Patients Using OCTA
Anti-vascular endothelial growth factor (VEGF) drugs are the mainstay of therapy for diabetic macular edema (DME), substantially improving visual acuity for many diabetics worldwide, and proving effective for treatment of both…
- Trial name
- IMPACT (NCT03246152)
- Testing
- Bevacizumab
- Where
- Egypt
- Volunteers
- 31 people
- Sponsor
- Cairo University
Diabetic Macular Edema, DME
COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
This is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.
- Conditions
- Diabetic Macular Edema, DME, Diabetic Macular Edema (DME)
- Trial name
- DME (NCT07449936)
- Testing
- EYP-1901, Aflibercept (2.0 mg)
- Where
- 73 sites in United States, Germany and 3 more
- Volunteers
- 240 people
- Sponsor
- EyePoint Pharmaceuticals, Inc.
Diabetic Macular Edema
Multiple Dose Safety and Efficacy of LKA651 in Patients With Diabetic Macular Edema
The primary objectives of this study were to evaluate the safety and efficacy of LKA651 in patients with macular edema from diabetic macular edema (DME),
- Trial name
- NCT03927690
- Testing
- LKA651, Lucentis
- Where
- 22 sites in United States, Germany and 3 more
- Volunteers
- 91 people
- Sponsor
- Novartis Pharmaceuticals
Diabetic Macular Edema
Suprachoroidal Injection of CLS-TA Alone or With Aflibercept in Subjects With Diabetic Macular Edema
This study is designed to demonstrate the safety and tolerability of suprachoroidal CLS-TA alone or in combination with intravitreal aflibercept in subjects with diabetic macular edema associated with diabetes mellitus.
- Trial name
- HULK (NCT02949024)
- Testing
- IVT Aflibercept, SC CLS-TA
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Clearside Biomedical, Inc.
Diabetic Macular Edema (DME)
Observational Study to Assess the Effect of Iluvien® in DME Patients Insufficiently Responsive to Available Therapies
This observational study aims to assess the safety and effect of Iluvien® in DME patients considered insufficiently responsive to available therapies in a real life setting in Germany.
- Trial name
- ILUMINATE (NCT02080091)
- Where
- Germany
- Volunteers
- 25 people
- Sponsor
- Alimera Sciences
Diabetic Macular Edema
Medico Economic Evaluation of Fluocinolone Acetonide Implant Versus Dexametheasone Implant in Resistant Diabetic Macular Oedema
Diabetic macular oedema (DME) is the main cause of visual impairment (or visual acuity) in patients with diabetic retinopathy, as it leads to progressive thickening of the retina, which in the long term leads to progressive death…
- Trial name
- EMMA (NCT04910503)
- Testing
- Dexamethasone intravitreal implant, Fluocinolone Acetonide Intravitreal Implant
- Where
- France
- Volunteers
- 106 people
- Sponsor
- Centre Hospitalier Universitaire Dijon